Form 4: MAIA Biotechnology Director Granted Stock Options Under Equity Plan

MAIA Biotechnology, Inc. Director Jean-Manasse Theagene was granted 20,380 stock options exercisable at $1.80 per share, vesting immediately.

Summary

• Jean-Manasse Theagene, a Director of MAIA Biotechnology, Inc. (MAIA), was granted 20,380 stock options.
• The options were granted on June 30, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
• Each stock option has an exercise price of $1.80.
• The options vest 100% on the date of the grant (June 30, 2025) and are exercisable beginning as of that date.
• The expiration date for these stock options is June 30, 2035.
• Following this reported transaction, Jean-Manasse Theagene beneficially owns 20,380 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice for executive compensation, aligning the director's financial interests with the long-term performance of the company and its shareholders. This is a routine transaction and does not indicate any unusual positive or negative developments.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance and value creation.
• The options vest 100% on the grant date and are immediately exercisable, providing immediate potential for the director to benefit from future stock price appreciation.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details a routine insider transaction, specifically the grant of stock options to a director, which is a common practice in the biotechnology industry and across publicly traded companies to incentivize and retain key personnel.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's interests with those of shareholders, potentially leading to improved long-term company performance.
• Employees: While this specific grant is to a director, equity incentive plans generally benefit employees by providing opportunities for ownership and incentivizing performance.

Next Steps

• The granted stock options can be exercised by Jean-Manasse Theagene at any time between June 30, 2025, and June 30, 2035, at the exercise price of $1.80 per share.

Key Dates

Keywords

MAIA Biotechnology, MAIA, Stock Options, Insider Transaction, Director Compensation, Equity Incentive Plan, Form 4, SEC Filing